Explore the words cloud of the INSIST project. It provides you a very rough idea of what is the project "INSIST" about.
The following table provides information about the project.
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
|Coordinator Country||Netherlands [NL]|
|Total cost||5˙550˙675 €|
|EC max contribution||5˙250˙675 € (95%)|
1. H2020-EU.3.1.5. (Methods and data)
|Duration (year-month-day)||from 2017-11-01 to 2021-10-31|
Take a look of project's partnership.
|1||ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM||NL (AMSTERDAM)||coordinator||908˙085.00|
|2||UNIVERSITE DE GENEVE||CH (GENEVE)||participant||771˙975.00|
|3||ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM||NL (ROTTERDAM)||participant||717˙500.00|
|4||THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD||UK (OXFORD)||participant||568˙125.00|
|5||UNIVERSITEIT VAN AMSTERDAM||NL (AMSTERDAM)||participant||545˙750.00|
|6||KATHOLIEKE UNIVERSITEIT LEUVEN||BE (LEUVEN)||participant||462˙500.00|
|7||NATIONAL UNIVERSITY OF IRELAND GALWAY||IE (Galway)||participant||425˙365.00|
|8||NEURAVI LIMITED||IE (GALWAY)||participant||416˙275.00|
|9||POLITECNICO DI MILANO||IT (MILANO)||participant||349˙600.00|
|10||INSTITUT DE RECHERCHES INTERNATIONALES SERVIER||FR (SURESNES)||participant||85˙500.00|
|11||M.V. LOMONOSOV MOSCOW STATE UNIVERSITY||RU (MOSCOW)||participant||0.00|
Stroke is the number one cause of disability in the Western world and the 3rd most common cause of death. Despite new treatment options with intra-arterial thrombectomy, still 2 out of 3 patients still have a poor outcome. The main goal of INSIST is to advance treatments of ischemic stroke and its introduction in clinical practice by realizing in silico clinical stroke trials in which stroke and treatment are modeled. We will generate virtual populations of stroke patients, generate and validate in silico models for intra-arterial thrombectomy, thrombosis and thrombolysis, and microvascular perfusion and neurological deterioration after stroke, and integrate the in silico models to realize an in silico clinical stroke trial. We are uniquely positioned by the availability of a large pool of clinical, imaging, histopathological, and outcome data from multiple recently finalized stroke trials, a large registry (totaling 4500 patients), and new trials that will start later this year (totaling 2500 patients). We will build a population model that takes this input to generate virtual populations of stroke patients addressing the wide variety of patient characteristics. We will build on existing and emerging in silico models to validate reusable models for stroke and stroke treatment with a strong interaction with experimenting modeling in laboratories. The in silico models and virtual populations will be combined to simulate clinical trials and validated by simulating and comparing finalized and currently running trials. The in silico models will be used to simulate clinical trials to evaluate effectiveness and safety of novel devices and medication, both for the device as well as the pharmacological industry. For the device industry, we will evaluate the optimal configuration of thrombectomy stents for reduction of thrombus fragmentation. From the perspective of the pharmacy industry, we will simulate the effect of increased TAFIa on the effectiveness of alteplase.
|Periodic reporting||Documents, reports||2019-09-02 12:14:23|
|Quality Assurance Plan||Documents, reports||2019-09-02 12:14:23|
|First report on dissemination, communication and sustainability||Websites, patent fillings, videos etc.||2019-09-02 12:14:23|
|First report on models for thrombosis and thrombolysis and combined model describing the models and performed experiments||Documents, reports||2019-09-02 12:14:23|
|Finite element meshes of patient specific clot and vessel geometries||Documents, reports||2019-09-02 12:14:23|
|First version of a virtual population of stroke patients (Module I)||Other||2019-09-02 12:14:23|
|Implementation of model of microvascular damage||Documents, reports||2019-09-02 12:14:23|
|Initial report on dissemination, exploitation and sustainability plan||Documents, reports||2019-09-02 12:14:23|
|Project Handbook||Documents, reports||2019-09-02 12:14:23|
|An in silico clinical stroke trial computing environment||Documents, reports||2019-09-02 12:14:23|
|Data Management Plan template||Documents, reports||2019-09-02 12:14:23|
|Consortium Agreement||Documents, reports||2019-09-02 12:14:23|
Take a look to the deliverables list in detail: detailed list of INSIST deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INSIST" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "INSIST" are provided by the European Opendata Portal: CORDIS opendata.
EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine.Read More
Common Infrastructure for National Cohorts in Europe, Canada, and AfricaRead More
Integrated and standardized NGS workflows for Personalised therapyRead More